Gut microbes, environmental toxins, and host health: how microbiome helps adaptation
Official title: The role of the gut microbiome in host adaptation to environmental xenobiotics - mechanisms and long-term consequences
Funded at University of California Berkeley · NIH-11398943 · Data updated 2026-11-12
This project studies how gut microbes help the body adapt to toxins like antibiotics and pesticides, using a C. elegans model to understand long-term health effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $361,125 |
| NIH project number | 5R01ES034012-03 |
| Project ID | NIH-11398943 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals interested in how microbiome health affects toxin responses or those at risk for exposure to environmental xenobiotics, though the study itself is preclinical using animal models.
✕Less likely to help
Direct patient benefit is unlikely for individuals not connected to exposure or microbiome health, as the work is conducted in a nematode model.
What this research studies
Researchers will use the C. elegans-worm model to examine how the gut microbiome changes in response to xenobiotics such as antibiotics and pesticides. They will explore the molecular pathways, including kinase signaling, that drive microbiome-driven adaptation and potential health trade-offs over the host’s lifespan. The study aims to uncover mechanisms by which microbial communities influence host resistance, vulnerability, and overall fitness in toxin-rich environments. Findings could illuminate how microbiome-host interactions contribute to variation in human responses to environmental chemicals and inform future interventions. The work leverages established worm models to connect microbes, toxins, and long-term health outcomes.
Why it matters
Potential benefit: If successful, this research could improve our understanding of how microbiomes shape responses to environmental toxins and pave the way for strategies to mitigate health risks associated with exposure.
How similar studies have gone: Previous work in microbiome and toxin exposure in model organisms suggests microbiome-driven adaptation is possible, though translating findings to humans remains an area of active research.
Where this research is happening
-
University of California Berkeley
Berkeley, United States Active
Researchers
- Principal investigator: Shapira, Michael — University of California Berkeley
- Study coordinator: Shapira, Michael
Related research
Other NIH-funded projects on the same topics.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
-
Aflatoxin exposure and child growth in Guatemala
A study in rural Guatemala will track how exposure to aflatoxin relates to growth and gut health in young children.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
How gut bacteria affect how cancer drugs work
This project looks at how the bacteria in your gut might change how well and with what side effects fluoropyrimidine cancer drugs like 5-FU work in people.
-
Gut bacteria and cancer drugs: how your gut may change chemotherapy effectiveness
This project studies how the gut microbiome might affect how well certain chemotherapy drugs work and their side effects in people with cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.